ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Population immunity, post-vaccine and post-infection antibody responses to influenza A (H3N2) subclade J.2 and K (J.2.4.1) viruses, Hong Kong, 2025.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Near real-time data on the human neutralizing antibody landscape to influenza virus in summer of 2026 shows antigenic advance of H3N2 subclade K region D mutants and H1N1 D.3.1.1 Sa mutants.bioRxiv : the preprint server for biology · 2026Article
- Near real-time data on the human neutralizing antibody landscape to influenza virus as of early 2026 to inform vaccine-strain selection.Virus evolution · 2026Article
- Influenza A/H3N2 epidemiology in England during the 2025 to 2026 season: a mathematical modelling study.Communications health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We assessed haemagglutination inhibition (HAI) antibody titres against 2025 influenza A(H3N2) J.2 vaccine reference viruses and the novel subclade K (J.2.4.1) in age-stratified Hong Kong sera (collected May-July 2025), vaccine recipients and sera from virologically confirmed subclade J.2.2 or K infections. In contrast to mono-specific ferret sera, human sera with high J.2 HAI titres cross-reacted strongly with subclade K. Recombinant haemagglutinin- or egg-based standard dose J.2 A(H3N2) vaccines boosted geometric mean titres to K virus 5.6-fold and 2.6-fold, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.